With new approaches in antibody-drug conjugates and drones to the next stage
15.10.2018
Araris Biotech and Voliro are the newest Kickers to pass Venture Kick stage 2. With a new approach for rapidly generating targeted cancer-drugs without antibody or cell-line engineering and a drone technology specifically designed to precisely fly in all directions, the two startups convinced the jury, taking home CHF 20’000 each.
.png) Timo Müller and Mina Kamel, Voliro
|
 |
.png) Philipp Spycher, Araris Biotech
|
|
Araris Biotech (PSI) - Biotech
Araris Biotech is focused on the development of antibody-drug conjugates (ADCs) having a well-defined and optimal antibody-to-drug ratio. The technology of Araris enables to rapidly generate highly efficient ADCs which do not require any antibody engineering. The startup aims to create a drug development platform for targeted therapies and diagnostic applications.
Voliro (ETHZ) – Electronics/mechanics, aerospace
Voliro aims to develop omnidirectional aerial vehicles (drones) with applications in infrastructure inspection, precision spray painting of complex 3D structures and façade cleaning, among other things.
Araris Biotech is focused on the development of antibody-drug conjugates (ADCs) having a well-defined and optimal antibody-to-drug ratio. The technology of Araris enables to rapidly generate highly efficient ADCs which do not require any antibody engineering. The startup aims to create a drug development platform for targeted therapies and diagnostic applications.
Voliro (ETHZ) – Electronics/mechanics, aerospace
Voliro aims to develop omnidirectional aerial vehicles (drones) with applications in infrastructure inspection, precision spray painting of complex 3D structures and façade cleaning, among other things.